- Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
-
Liu CH, Chen CY, Su WW, Liu CJ, Lo CC, Huang KJ, Chen JJ, Tseng KC, Chang CY, Peng CY, Shih YL, Huang CS, Kao WY, Yang SS, Tsai MC, Wu JH, Chen PY, Su PY, Hwang JJ, Fang YJ, Lee PL, Tseng CW, Lee FJ, Lai HC, Hsieh TY, Chang CC, Chang CH, Huang YJ, Kao JH
- KMID: 2520841
- Clin Mol Hepatol.
- 2021 Oct;27(4):575-588.
- doi: 10.3350/cmh.2021.0155
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. Methods: We included 107 patients with Child-Pugh... -
- CITED
-
- Close
- SHARE
-
- Close
